LogicBio Therapeutics (LPRO) Downgraded by Zacks Investment Research to Hold

LogicBio Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  LogicBio Therapeutics Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More LogicBio Therapeutics (LPRO) Downgraded by Zacks Investment Research to Hold

Earnings : What to expect LogicBio Therapeutics (NASDAQ:LOGC)

Earnings results for LogicBio Therapeutics , Analyst Opinion on LogicBio Therapeutics , Earnings and Valuation of (NASDAQ:LOGC), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings : What to expect LogicBio Therapeutics (NASDAQ:LOGC)

Analysts Estimate Report : What to Look Out for LogicBio Therapeutics (NASDAQ:LOGC)

Earnings results for LogicBio Therapeutics , Analyst Opinion on LogicBio Therapeutics , Earnings and Valuation of (NASDAQ:LOGC), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Analysts Estimate Report : What to Look Out for LogicBio Therapeutics (NASDAQ:LOGC)

Will earnings report, end it’s winning streak? LogicBio Therapeutics (NASDAQ:LOGC)

Earnings results for LogicBio Therapeutics , Analyst Opinion on LogicBio Therapeutics , Earnings and Valuation of (NASDAQ:LOGC), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Will earnings report, end it’s winning streak? LogicBio Therapeutics (NASDAQ:LOGC)

Does Earnings Surprise History Hold Any Clue for LogicBio Therapeutics (NASDAQ:LOGC)

Earnings results for LogicBio Therapeutics , Analyst Opinion on LogicBio Therapeutics , Earnings and Valuation of (NASDAQ:LOGC), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Does Earnings Surprise History Hold Any Clue for LogicBio Therapeutics (NASDAQ:LOGC)